Literature DB >> 15531339

Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis.

Lindsay M Smithen1, Richard F Spaide.   

Abstract

PURPOSE: To report combined treatment of photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide injection for subfoveal neovascularization secondary to bilateral idiopathic juxtafoveal telangiectasis.
DESIGN: Interventional case report.
METHOD: A patient with a subfoveal neovascularization secondary to bilateral idiopathic juxtafoveal telangiectasis was treated with PDT plus an intravitreal injection of 4 mg of triamcinolone acetonide.
RESULTS: Leakage in the late-phase of fluorescein angiography resolved with attenuation of telangiectatic vessels and improvement in visual acuity from 20/200 to 20/50. At 9 months post-treatment, recurrent leakage was treated with repeat PDT and intravitreal triamcinolone. One year after initial presentation, visual acuity was 20/60 with no leakage on fluorescein.
CONCLUSION: Combined treatment with PDT and intravitreal triamcinolone acetonide resulted in regression of a subfoveal neovascular membrane and improvement in visual acuity during the course of follow-up.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531339     DOI: 10.1016/j.ajo.2004.05.073

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  The problem of pressure elevation associated with intravitreal triamcinolone.

Authors:  M D Conway
Journal:  Br J Ophthalmol       Date:  2006-08       Impact factor: 4.638

2.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Javier A Montero; Jose M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

3.  Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia.

Authors:  Teresa Barth; Florian Zeman; Horst Helbig; Maria-Andreea Gamulescu
Journal:  Int Ophthalmol       Date:  2017-01-21       Impact factor: 2.031

4.  Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.

Authors:  Rodrigo Jorge; Rogério A Costa; Daniela Calucci; Ingrid U Scott
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-29       Impact factor: 3.117

Review 5.  Intraocular sustained-release delivery systems for triamcinolone acetonide.

Authors:  Saffar Mansoor; Baruch D Kuppermann; M Cristina Kenney
Journal:  Pharm Res       Date:  2009-01-28       Impact factor: 4.200

6.  One-year results of verteporfin therapy for subretinal neovascularization associated with type 2A parafoveal telengiectasia.

Authors:  Nazimul Hussain; Taraprasad Das; Rohit Khanna; L S Mohan Ram; Kallukuri Sumasri
Journal:  Clin Ophthalmol       Date:  2007-12

7.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 8.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

9.  Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia.

Authors:  Subrata Mandal; Pradeep Venkatesh; Zahir Abbas; Rajpal Vohra; Satpal Garg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-03-08       Impact factor: 3.117

10.  Clinical features of idiopathic juxtafoveal telangiectasis in Koreans.

Authors:  Seung Woo Lee; Sung Min Kim; Yun Taek Kim; Se Woong Kang
Journal:  Korean J Ophthalmol       Date:  2011-07-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.